Single dose of Pain Therapeutics’ PTI-188 decreased melanoma tumors: Study

Pain Therapeutics, Inc. today announced encouraging clinical data with PTI-188, an early-stage for metastatic melanoma. Metastatic melanoma is a lethal form of skin in which patients typically have a median survival time of 9 months.


Read more

Related posts

Leave a Reply